Clinical trial NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies
Official title: A Phase Ia Trial of ATI-2231 in Advanced Solid Tumor Malignancies
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Advanced Solid Tumor
Advanced Solid Tumor Malignancies
Keywords: MK2 inhibitor
ATI-2231
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Aclaris Therapeutics, Inc.
First posted: 2023-03-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.


Eligibility criteria: Inclusion Criteria:

* Biopsy-proven advanced solid tumor malignancy including head and neck cancer, non-small cell lung cancer, gastrointestinal adenocarcinoma, pancreatic adenocarcinoma, prostate cancer, bladder cancer, and breast cancer.
* Eligible patients must have an advanced solid malignancy above, for which standard curative or palliative therapies do not exist or are no longer effective.
* Measurable or non-measurable but evaluable disease by RECIST v 1.1.
* Patients must have archival tissue sample available from prior metastatic biopsy. If no tissue is available, patient may still be able to enroll with PI approval.
* At least 18 years of age.
* ECOG performance status ≤ 2
* Life expectancy of at least 12 weeks.
* Adequate bone marrow and organ function as defined below:

  * Leukocytes ≥ 3 K/cumm
  * Absolute neutrophil count (ANC) ≥ 1.5 K/cumm
  * Platelets ≥ 100 K/cumm
  * Total bilirubin ≤ 1.5 x IULN (unless patient has known Gilberts disease)
  * AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
  * Creatinine clearance \> 60 mL/min by Cockcroft-Gault
* The effects of ATI-2231on the developing human fetus are unknown. For this reason, women of childbearing potential and men who are heterosexually active must agree to use adequate contraception as specified in the protocol. Contraception should continue for 1 month (for women) or 3 months (for men) after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
* Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

* Patients may not have received the following investigational or SOC therapies within the below specified time frames prior to C1D1:

  * Denosumab or bisphosphonates within 4 weeks
  * Radiation therapy within 1 week
  * Systemic chemotherapy, including antibody drug conjugates with chemotherapy payload, within 3 weeks.
  * Immunotherapy within 3 weeks
  * Oral chemotherapy or molecularly targeted therapy within 5 half-lives of the agent.
  * Endocrine therapies do not have a required washout and may be continued until C1D1.
* Untreated brain metastases. Patients with treated brain metastases are eligible if they show no evidence of progression and are off steroids or on stable/decreasing steroid dose.
* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ATI-2231.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
* Patients with known HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
* Screening resting QTcF above 460 ms (average of triplicate).

Primary outcomes:
measure: Number of participants experiencing adverse events
timeFrame: From baseline through 30 days after end of treatment (estimated to be 7 months)
Secondary outcomes:
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax)
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by elimination rate constant
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent volume of distribution
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent clearance
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax)
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by half-life (T1/2)
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-24h)
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, and 24 hours post dose cycle 1 (estimated to be 1 day)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-infinity)
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t)
timeFrame: Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax)
timeFrame: Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by trough concentration
timeFrame: Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t)
timeFrame: Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
measure: Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax)
timeFrame: Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
measure: ATI-2231 pharmacokinetics (PK) as measured by trough concentration
timeFrame: Cycle 3 day 1 (each cycle is 21 days)
measure: ATI-2231 pharmacokinetics (PK) as measured by trough concentration
timeFrame: Cycle 4 day 1 (each cycle is 21 days)
measure: ATI-2231 pharmacokinetics (PK) as measured by trough concentration
timeFrame: Cycle 5 day 1 (each cycle is 21 days)
measure: ATI-2231 pharmacokinetics (PK) as measured by trough concentration
timeFrame: Cycle 6 day 1 (each cycle is 21 days)
Other outcomes:
Locations:
Study officials:
affiliation: Washington University School of Medicine
name: Cynthia X Ma, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: